Treatment of early-onset schizophrenia

Current Opinion in Psychiatry

Volumn 23, Issue 4, 2010, Pages 304-310

  Mattai, Anand K ^a   Hill, Julia L ^b   Lenroot, Rhoshel K ^a,b,c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Adolescent; Antipsychotic; Child; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; HALOPERIDOL; LITHIUM; LOXAPINE SUCCINATE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A RECEPTOR; THIORIDAZINE; TIOTIXENE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADJUVANT THERAPY; ADOLESCENT; AFFECTIVE PSYCHOSIS; AGGRESSION; AKATHISIA; BIPOLAR DISORDER; BRAIN DEVELOPMENT; CHILD; CHILD CARE; CHILD DEVELOPMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITIVE THERAPY; CONFUSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIETARY INTAKE; DISABILITY; DISEASE EXACERBATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EARLY DIAGNOSIS; EARLY INTERVENTION; EARLY ONSET SCHIZOPHRENIA; EXERCISE; EXTRAPYRAMIDAL SYMPTOM; FAMILY THERAPY; FOLLOW UP; GOLD STANDARD; GRAY MATTER; HALLUCINATION; HEALTH CARE COST; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; MAJOR DEPRESSION; MEDICAL RECORD REVIEW; MENTAL HEALTH CARE; METABOLIC DISORDER; METABOLISM; MOOD DISORDER; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PHENOTYPE; POLYPHARMACY; POSITIVE AND NEGATIVE SYNDROME SCALE; PREVENTION; PROLACTIN BLOOD LEVEL; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SOCIAL ADAPTATION; SOCIAL INTERACTION; TARDIVE DYSKINESIA; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CHILD; HUMANS; PSYCHOTHERAPY; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 77953541455     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e32833b027e     Document Type: Review

References (66)

1. Bleuler E. Dementia Praecox or the group of schizophrenias. New York: International Universities Press; 1911/1950.
2. Kraepelin E. Dementia praecox and paraphrenia. 8th ed. London: E. and S. Livingstone; 1899/1919.
3. McKenna K, Gordon CT, Lenane M, et al. Looking for childhood-onset schizophrenia: the first 71 cases screened. J Am Acad Child Adolesc Psychiatry 1994; 33:636-644.
4. Beitchman JH. Childhood schizophrenia: a review and comparison with adultonset schizophrenia. Psychiatr Clin North Am 1985; 8:793-814.
5. Hafner H. Special issue Schizophrenia in Childhood and Adolescence [editorial]. Eur Arch Psychiatry Clin Neurosci 1995; 245:57-60.
6. Nicolson R, Rapoport JL. Childhood-onset schizophrenia: rare but worth studying. Biol Psychiatry 1999; 46:1418-1428.
7. Rapoport JL, Addington A, Frangou S. The neurodevelopmental model of schizophrenia: what can very early onset cases tell us? Curr Psychiatry Rep 2005; 7:81-82.
8. Asarnow JR. Childhood-onset schizotypal disorder: a follow-up study and comparison with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 2005; 15:395-402.
9. Tanaka S, Watanabe K. Transcranial direct current stimulation: a new tool for human cognitive neuroscience. Brain Nerve 2009; 61:53-64.
10. Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, just the facts 4: clinical features and conceptualization. Schizophr Res 2009; 110:1-23.
11. Roy A, Pompili M. Management of schizophrenia with suicide risk. Psychiatr Clin North Am 2009; 32:863-883.
12. Masi G, Mucci M, Pari C. Children with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs 2006; 20:841-866.
13. Ulloa RE, Birmaher B, Axelson D, et al. Psychosis in a pediatric mood and anxiety disorders clinic: phenomenology and correlates. J Am Acad Child Adolesc Psychiatry 2000; 39:337-345.
14. McClellan J, McCurry C. Early onset psychotic disorders: diagnostic stability and clinical characteristics. Eur Child Adolesc Psychiatry 1999; 8 (Suppl 1):I13-I19.
15. Patterson TL, Leeuwenkamp OR. Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr Res 2008; 100:108-119.
16. McGurk SR, Twamley EW, Sitzer DI, et al. A meta-analysis of cognitive remediation in schizophrenia. Am J Psychiatry 2007; 164:1791-1802.
17. Petersen L, Jeppesen P, Thorup A, et al. A randomised multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 2005; 331:602.
18. Eack SM, Greenwald DP, Hogarty SS, et al. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv 2009; 60:1468-1476.
19. Pool D, Bloom W, Mielke DH, et al. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr Ther Res Clin Exp 1976; 19:99-104.
20. Realmuto GM, Erickson WD, Yellin AM, et al. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry 1984; 141:440-442.
21. Spencer EK, Kafantaris V, Padron-Gayol MV, et al. Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol Bull 1992; 28:183-186.
22. Sporn A, Gogtay N, Ortiz-Aguayo R, et al. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003; 13:401-404.
23. Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a doubleblind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006; 63:721-730.
24. Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and high-dose olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2008; 63:524-529.
25. Kim Y, Kim BN, Cho SC, et al. Long-term sustained benefits of clozapine treatment in refractory early onset schizophrenia: a retrospective study in Korean children and adolescents. Hum Psychopharmacol 2008; 23:715-722.
26. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008; 165:1420-1431.
27. Bachmann CJ, Lehr D, Theisen FM, Preiss M. Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review. Pharmacopsychiatry 2009; 42:153-157.
28. Haas M, Unis AS, Armenteros J, et al. A 6-week, andomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J Child Adolesc Psychopharmacol 2009; 19:611-621.
29. Keshavan MS, Roberts M, Wittmann D. Guidelines for clinical treatment of early course schizophrenia. Curr Psychiatry Rep 2006; 8:329-334.
30. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009; 23:649-659.
31. Findling RL, Schulz SC, Reed MD, Blumer JL. The antipsychotics: a pediatric perspective. Pediatr Clin North Am 1998; 45:1205-1232.
32. Madaan V, Dvir Y, Wilson DR. Child and adolescent schizophrenia: pharmacological approaches. Expert Opin Pharmacother 2008; 9:2053-2068.
33. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of secondgeneration antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008; 34:60-71.
34. Pandina G, Kushner S, Singer J, et al. Comparison of two risperidone dose ranges in adolescents with schizophrenia. Poster presentation, 54th Annual Meeting of the American Academy of Child and Adolescent Psychiatry; Boston, Massachusetts, USA; 2007.
35. Gogtay N, Rapoport J. Clozapine use in children and adolescents. Expert Opin Pharmacother 2008; 9:459-465.
36. Rani F, Murray ML, Byrne PJ, Wong IC. Epidemiologic features of antipsychotic prescribing to children and adolescents in primary care in the United Kingdom. Pediatrics 2008; 121:1002-1009.
37. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009; 39:1591-1602.
38. McClellan J, Sikich L, Findling RL, et al. Treatment of early-onset schizophrenia spectrum disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry 2007; 46:969-978. (Pubitemid 47220681)
39. Domino ME, Swartz MS. Who are the new users of antipsychotic medications? Psychiatr Serv 2008; 59:507-514.
40. Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am 2006; 15:177-206.
41. Jerrell JM, McIntyre RS. Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 2008; 23:283-290.
42. Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of secondgeneration antipsychotic medications during first-time use in children and adolescents. JAMA 2009; 302:1765-1773.
43. Fraguas D, Merchan-Naranjo J, Laita P, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 2008; 69:1166-1175.
44. Fleischhaker C, Heiser P, Hennighausen K, et al. Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 2008; 115:1599-1608.
45. Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry 2008; 20:195-201.
46. Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 2009; 19:629-635.
47. Walter G, DeLaroche A, Soh N, et al. Side effects of second-generation antipsychotics: the experiences, views and monitoring practices of Australian child psychiatrists. Australas Psychiatry 2008; 16:253-262.
48. Correll CU. Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry 2008; 69 (Suppl 4):26-36.
49. Correll CU. Acute and long-term adverse effects of antipsychotics. CNS Spectr 2007; 12:10-14.
50. Correll CU. Antipsychotic polypharmacy, part 1: shotgun approach or targeted cotreatment? J Clin Psychiatry 2008; 69:674-675.
51. Jerrell JM, McIntyre RS. Health-care costs of pediatric clients developing adverse events during treatment with antipsychotics. Value Health 2009; 12:716-722.
52. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008; 65:28-37.
53. Klosterkotter J, Ruhrmann S, Schultze-Lutter F, et al. The European Prediction of Psychosis Study (EPOS): integrating early recognition and intervention in Europe. World Psychiatry 2005; 4:161-167.
54. Phillips LJ, Nelson B, Yuen HP, et al. Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiatry 2009; 43:818-829.
55. Ruhrmann S, Schultze-Lutter F, Klosterkotter J. Intervention in the at-risk state to prevent transition to psychosis. Curr Opin Psychiatry 2009; 22:177-183.
56. Schultze-Lutter F, Ruhrmann S, Berning J, et al. Basic symptoms and ultrahigh risk criteria: symptom development in the initial prodromal state. Schizophr Bull 2010; 36:182-191.
57. Phillips LJ, McGorry PD, Yuen HP, et al. Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 2007; 96:25-33.
58. Ruhrmann S, Bechdolf A, Kuhn KU, et al. Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 2007; 51:s88-s95.
59. McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultra high risk for psychosis: a review and future directions. J Clin Psychiatry 2009; 70:1206-1212.
60. Fusar-Poli P, Valmaggia L, McGuire P. Can antidepressants prevent psychosis? Lancet 2007; 370:1746-1748.
61. Amminger GP, Berger GE, Schafer MR, et al. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebocontrolled pilot study. Biol Psychiatry 2007; 61:551-553.
62. Yung AR, Yuen HP, Berger G, et al. Declining transition rate in ultra high risk (prodromal) services: dilution or reduction of risk? Schizophr Bull 2007; 33:673-681.
63. McGorry PD, Purcell R, Hickie IB, et al. Clinical staging: a heuristic model for psychiatry and youth mental health. Med J Aust 2007; 187:S40-S42.
64. Arango C, Moreno C, Martinez S, et al. Longitudinal brain changes in earlyonset psychosis. Schizophr Bull 2008; 34:341-353.
65. Mattai A, Chavez A, Greenstein D, et al. Effects of clozapine and olanzapine on cortical thickness in childhood-onset schizophrenia. Schizophr Res 2010; 116:44-48.
66. Stanford AD, Sharif Z, Corcoran C, et al. rTMS strategies for the study and treatment of schizophrenia: a review. Int J Neuropsychopharmacol 2008; 11:563-576.